[MARKET ANALYSIS] T-notes eked mild gains but with upside capped after the choppy reaction to the inline US CPI data
Newsquawk Staff ·
USTs: +2.5 ticks
- Ekes mild gains but with upside limited after a choppy reaction to the inline US CPI data, which saw the Treasury curve bull steepen, led by declines in front-end yields, while the latest 10-year note auction was not as strong as the previous but remained better than recent averages, pointing to healthy underlying demand for duration.
Bunds: Flat
- Lacks direction following the prior day's whipsawing and absence of any revisions to German inflation data.
JGBs: +5 ticks
- Demand is contained after recent fluctuations, while softer-than-expected PPI data did little to spur prices.
What it means
An inline CPI print with a choppy initial reaction is the classic signature of a market positioned for a surprise in either direction and getting neither: the knee-jerk moves in both directions get faded, and the curve eventually resolves toward the front end once the data remove a tail risk rather than create one. Bull steepening on an in-line inflation release fits the established pattern where the two-year, being the point most sensitive to the policy path, rallies hardest when the hurdle for hawkish repricing is not met, while the long end takes its cue from supply and term-premium dynamics. The auction result described, softer than the prior stop but above recent averages, is the usual sequencing tell: demand for duration holding up at concession rather than chasing the rally is generally read as constructive but not emphatic, and the next supply in the calendar tends to be where that read gets tested. Bunds going flat on unrevised national inflation data is standard behaviour ahead of the euro-area aggregate, where revisions at the country level rarely matter unless they alter the weighted print. JGBs shrugging off soft producer prices is consistent with a market that prices domestic wholesale data as second-order relative to policy communication and global duration direction. The forward points of interest are the follow-through in the front-end versus belly, and whether the next auction tails or stops through.
- Week in Focus 26-30th October 2026: FOMC, BoC, RBNZ, ECB, BoJ Policy Decisions, US PCE
- US TREASURY WRAP: T-NOTE FUTURES (Z6) SETTLE 8 TICKS LOWER AT 106-05
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)
- Newsquawk European Market Wrap - 23rd October 2026
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce
Related headlines
- Newsquawk Daily Economic Release - 26th October 202619 hours ago
- US Midterm Preview: Democrats Favoured to Flip the House, Senate Too Close to Call13 hours ago
- Newsquawk Weekly Economic Release 26th - 30th October 2026 19 hours ago
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation20 hours ago
- US FX WRAP: DXY rises; hawkish Japan CPI report/BoJ sources; EUR hit on weak PMI data14 hours ago
- CRUDE WRAP: WTI (Z6) SETTLES USD 3.80 HIGHER AT USD 103.27/BBL; BRENT (Z6) SETTLES USD 3.55 HIGHER AT USD 116.72/BBL14 hours ago
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL15 hours ago
- US Market Wrap: Stocks hit as oil rally stokes inflation concerns; Trump keeps Iran strikes on the table13 hours ago
- [MARKET UPDATE] Spot gold slips below USD 4k/oz, but remains just above the USD 3986/oz low. Further, modest, pressure seen in equity futures.19 hours ago
- Brazilian IPCA mid-month CPI (Oct YY) 4.62% vs. Exp. 4.73% (Prev. 4.47%)21 hours ago
- Brazilian IPCA mid-month CPI (Oct MM) 0.32% vs. Exp. 0.43% (Prev. 0.70%)21 hours ago
- US President Trump says we’re close to ending, I hope, the Russia-Ukraine war13 hours ago
- White House says President Trump has further modified Canadian products subject to tariffs under Section 338; tariff changes will take effect on 30th October 202613 hours ago
- US President Trump, on Iran, says we may do another operation against Iran; doubts Iran will say ‘let’s get down to business’13 hours ago
- US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease13 hours ago